Gilead Sciences' top products based on revenue 2020-2022

Leading products of Gilead Sciences from 2020 to 2022 based on revenue

Show detailed source information?
Register for free
Already a member?
Log in

Use Ask Statista Research Service

Release date

February 2023



Survey time period

2020 to 2022

Special properties

Supplementary notes

* Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.
** Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).

Open this statistic in...
Citation formats
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$189 USD $149 USD / Month *
in the first 12 months
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Other statistics that may interest you

Other statistics that may interest you Statistics on

About the industry


About the region


Selected statistics


Other regions


Related statistics


Further related statistics

Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Learn more about how Statista can support your business.